Goldman Sachs
ADMS

Goldman Sachs’s Adamas Pharmaceuticals ADMS Stock Holding History

Goldman Sachs’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-98,300
Closed -$2.35M – 6151
2018
Q1 		$2.35M Buy
+98,300
New +$3.1M ﹤0.01% 3482
2017
Q4 		– Sell
-150,000
Closed -$3.18M – 6780
2017
Q3 		$3.18M Buy
+150,000
New +$2.75M ﹤0.01% 3569

Goldman Sachs's ADMS Position: Q4 2021 in Review

Goldman Sachs sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 38,802 shares — an estimated $190K sold.

Goldman Sachs first reported a position in ADMS in Q2 2014 and held it in 28 quarters. The position peaked at $5.83M in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

  • Goldman Sachs reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Goldman Sachs sold 38,802 Adamas Pharmaceuticals shares in Q4 2021, an estimated $190K.
  • Goldman Sachs first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 28 quarters.
  • Goldman Sachs's Adamas Pharmaceuticals position peaked at $5.83M in Q4 2017.
  • 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.